Additionally, hsa-miR-199a-3p downregulates BRCA1, impairing DNA repair and enhancing sensitivity to cisplatin and PARP inhibitors in triple-negative breast cancer (TNBC) [23]. Here, BRCA1 is linked to triple-negative breast carcinoma.